NEWS HIGHLIGHTSMedia Articles Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)
New Consortium Paves The Way For Improved Treatment Of Hypertension And Associated Vascular Complications
Source: Hypertension News From Medical News Today [2009.11.18]
Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.
Kids with CKD Often Have Masked Hypertension (CME/CE)
Source: MedPage Today Nephrology [2009.11.13]
Many children with chronic kidney disease may have undetected hypertension, placing them at risk for enlarged hearts and future cardiovascular disease, a cross-sectional study showed.
Key Player Identified In Cascade That Leads To Hypertension-Related Kidney Damage
Source: Hypertension News From Medical News Today [2009.11.06]
A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. Medical College of Georgia researchers have found endothelin, a powerful blood vessel constrictor and inflammatory peptide, increases the number of T cells in the kidneys, which helps recruit other immune cells, causing inflammation and destruction.
A Recipe For Hypertension: High Fructose Corn Syrup
Source: Hypertension News From Medical News Today [2009.10.31]
A diet high in fructose increases the risk of developing high blood pressure (hypertension), according to a paper presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, California. The findings suggest that cutting back on processed foods and beverages that contain high fructose corn syrup (HFCS) may help prevent hypertension.
Hypertension Guidelines Reappraised In Light Of New Research
Source: Hypertension News From Medical News Today [2009.10.30]
A Task Force of the European Society of Hypertension have released the official European guidelines on the management and treatment of hypertension. The guidelines are an update of those published in 2007, and will be published in the November issue of the Journal of Hypertension.
Published Studies Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)
Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension. [2009.01]
Among angiotensin receptor blockers (ARBs), telmisartan is suggested to function as a partial agonist of peroxisome proliferator-activated receptor-gamma (PPAR gamma) and to improve lipid and glucose metabolism. Clinical benefits of telmisartan over other ARBs may be apparent in combination with diuretics, which have harmful influences on lipid and glucose metabolism...
The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. [2008.06]
BACKGROUND: To compare the tolerability and safety of telmisartan +/- hydrochlorothiazide (HCTZ)... CONCLUSION: The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities.
Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. [2008.02]
In 2004-2005, the antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg combined with hydrochlorothiazide 25 mg were assessed in a large placebo-controlled trial in patients with stages 1 and 2 hypertension and demonstrated that both agents were highly effective in lowering blood pressure (BP) compared with placebo and that telmisartan lowered BP significantly greater than valsartan...
Nilotinib. [2008]
Nilotinib is an orally administered BCR-ABL tyrosine kinase inhibitor that has shown good clinical efficacy in imatinib-resistant or -intolerant, Philadelphia chromosome-positive, chronic myeloid leukaemia (CML) in a phase I/II trial. The phase I component of the trial established the dosage regimen used in the phase II part of the trial, which included several arms...
Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. [2006.03]
The aim of this study was to compare the effects of telmisartan/hydrochlorothiazide (HCTZ) vs lisinopril/HCTZ combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. A total of 160 patients, 76 men and 84 women, aged 61-75 years, with sitting diastolic blood pressure (DBP)>90 mmHg and <110 mmHg and systolic blood pressure (SBP)>140 mmHg were randomized to receive temisartan 80 mg/HCTZ 12.5 mg o.d...
Clinical Trials Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)
Telmisartan80mg/hydrochlothiazide12.5mg (Micardis Plus) ABPM Study in China [Completed]
to evaluate the trough and peak effect of once daily MICARDIS PLUS? (Telmisartan 80mg /
hydrochlorot hiazide 12. 5 mg) by 24 ABPM in patients with mild to moderate essential
hypertension
INNOVATION Study - Telmisartan (Micardis?) in Incipient Diabetic Nephropathy [Completed]
The aim of this study is to compare the preventive effect of Telmisartan (Micardis?) versus
placebo control on the transition to overt nephropathy in patients with diabetic nephropathy
manifesting mic roalbuminuria associated with type II diabetes, and to evaluate the efficacy
and safety of Telmisart an (Micardis?, Gliosartan?, Kinzal?, Kinzalmono?, Predxal?, Pritor?,
Samertan?, Telmisartan?) for di abetic nephropathy patients.
Telmisartan80/HCTZ25 Versus telmisartan80/HCTZ12.5 in Hypertension Not Responding to telmisartan80/HCTZ12.5 [Completed]
The primary objective of this trial is to demonstrate that a fixed dose combination of
telmisartan 8 0 mg plus hydrochlorothiazide 25 mg (T80/H25) is superior in reducing blood
pressure after eight wee ks compared with a fixed dose combination of telmisartan 80 mg plus
hydrochlorothiazide 12. 5 mg (T80
/H12. 5) in patients who fail to respond to six weeks treatment with T80/H12. 5.
Trial of Telmisartan 80mg/HCTZ 12.5mg and Telmisartan 40mg/HCTZ 12.5mg in Patients With Hypertension [Completed]
The objective of this trial is to assess the safety and efficacy of 52 weeks of open-label
treatment with the fixed dose combination of telmisartan 80 mg plus HCTZ 12. 5 mg and
telmisartan 40 mg plus H CTZ 12. 5 mg in patients with essential hypertension.
Non-Responder Study to Telmisartan 40mg [Completed]
The objective of this trial is to demonstrate that the fixed dose combination of telmisartan
40 mg a nd HCTZ 12. 5 mg is superior to the monocomponent of telmisartan (Micardis?,
Gliosartan?, Kinzal?, Ki nzalmono?, Predxal?, Pritor?, Samertan?, Telmisartan?) 40 mg in
patients with essential hypertension who fail to respond adequately to telmisartan
monotherapy.
|
